Emily Bergsland, MD
Professor
Medicine
School of Medicine

Dr. Bergsland leads a clinical-translational research program focused on neuroendocrine neoplasms of all grades, which includes clinical trials and collaborative studies related to biomarkers, imaging and clinical outcomes. She is past president of the North American Neuroendocrine Tumor Society, a longstanding member of the NCCN Neuroendocrine Tumor Guidelines panel, and past chair of the NET Task Force of the NCI Gastrointestinal Steering Committee.

• A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
  Cancer research communications 2024 Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P,…
• Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2.
  JCO precision oncology 2024 Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P
• Long-Term Survival Outcomes After Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
  Annals of surgical oncology 2024 Yogo A, Paciorek A, Kasai Y, Moon F, Hirose K, Corvera CU, Bergsland EK, Nakakura EK
• Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors.
  CA: a cancer journal for clinicians 2024 Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O'Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, …
• Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center.
  The oncologist 2024 Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom …
• The Impact of Posttreatment Imaging in Peptide Receptor Radionuclide Therapy.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2024 Yadav S, Lawhn-Heath C, Paciorek A, Lindsay S, Mirro R, Bergsland EK, Hope TA
• Survival outcomes for lung neuroendocrine tumors in California differ by sociodemographic factors.
  Endocrine-related cancer 2023 Mulvey CK, Paciorek A, Moon F, Steiding P, Shih B, Gubens MA, Zhang L, Bergsland EK, Cheng I
• The effect of hormonal secretion on survival in adrenocortical carcinoma: A multi-center study.
  Surgery 2023 Sada A, Foster TR, Al-Ward R, Sawani S, Charchar H, Pishdad R, Ben-Shlomo A, Dy BM, Lyden ML, Bergsland E, Jasim S, Raj N, Shank JB, Hamidi O, Hamrahian AH, Chambô JL, Srougi V, Fragoso MC, Graham PH,…
• Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2023 Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC…
• Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
  Journal of the National Cancer Institute 2023 Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, …
• The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow.
  Journal of medical Internet research 2023 Majmudar S, Graff SL, Kays M, Braz BX, Matt-Amaral L, Markham MJ, Subbiah IM, Bergsland E, Jain S
• Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors.
  Cancers 2023 Varghese DG, Del Rivero J, Bergsland E
• Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms.
  Endocrine-related cancer 2023 Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA
• Preclinical Models of Adrenocortical Cancer.
  Cancers 2023 Sedlack AJH, Hatfield SJ, Kumar S, Arakawa Y, Roper N, Sun NY, Nilubol N, Kiseljak-Vassiliades K, Hoang CD, Bergsland EK, Hernandez JM, Pommier Y, Del Rivero J
• Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.
  British journal of cancer 2023 Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK
• Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time.
  Journal of neuroendocrinology 2023 Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK
• Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review.
  Clinical genitourinary cancer 2023 Le BK, McGarrah P, Paciorek A, Mohamed A, Apolo AB, Chan DL, Reidy-Lagunes D, Hauser H, Rivero JD, Whitman J, Batty K, Zhang L, Raj N, Le T, Bergsland E, Halfdanarson TR
• Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis.
  European journal of cancer (Oxford, England : 1990) 2023 Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, Chan JA, LaFerriere H, Ramirez RA, Berlin J, Dasari A
• Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023 Umetsu SE, Kakar S, Basturk O, Kim GE, Chatterjee D, Wen KW, Hale G, Shafizadeh N, Cho SJ, Whitman J, Gill RM, Jones KD, Navale P, Bergsland E, Klimstra D, Joseph NM
• Preclinical Models of Neuroendocrine Neoplasia.
  Cancers 2022 Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J
• DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
  The oncologist 2022 Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M
• A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies.
  Cancer research communications 2022 Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN
• Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung.
  JCO precision oncology 2022 Sun F, Grenert JP, Tan L, Van Ziffle J, Joseph NM, Mulvey CK, Bergsland E
• Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 Hope TA, Pavel M, Bergsland EK
• Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists.
  Abdominal radiology (New York) 2022 Galgano SJ, Morani AC, Gopireddy DR, Sharbidre K, Bates DDB, Goenka AH, Arif-Tiwari H, Itani M, Iravani A, Javadi S, Faria S, Lall C, Bergsland E, Verma S, Francis IR, Halperin DM, Chatterjee D, …
• Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021 Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA
• Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips.
  Biosensors & bioelectronics 2021 Sun N, Yang Y, Miao H, Redublo P, Liu H, Liu W, Huang YW, Teng PC, Zhang C, Zhang RY, Smalley M, Yang P, Chou SJ, Huai K, Zhang Z, Lee YT, Wang JJ, Wang J, Liang IY, Zhang TX, Zhang D, Liang L, Weiss …
• Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study.
  Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021 Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S
• Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review.
  The oncologist 2021 Chan DL, Bergsland EK, Chan JA, Gadgil R, Halfdanarson TR, Hornbacker K, Kelly V, Kunz PL, McGarrah PW, Raj NP, Reidy DL, Thawer A, Whitman J, Wu L, Becker C, Singh S
• Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
  Journal of the National Comprehensive Cancer Network : JNCCN 2021 Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan …
• Outcomes after high-dose radiation in the management of neuroendocrine neoplasms.
  PloS one 2021 Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M
• The Immunotherapy Landscape in Adrenocortical Cancer.
  Cancers 2021 Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, Pommier Y, Del Rivero J
• Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study.
  Neuroendocrinology 2021 Hörsch D, Anthony L, Gross DJ, Valle JW, Welin S, Benavent M, Caplin M, Pavel M, Bergsland E, Öberg K, Kassler-Taub KB, Binder P, Banks P, Lapuerta P, Kulke MH
• Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database.
  Pancreas 2021 Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K
• Minimally Invasive Surgery for Ileal Neuroendocrine Tumors.
  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2021 Mahuron KM, Kasai Y, Javeed ZA, Bergsland EK, Hirose K, Corvera CU, Nakakura EK
• Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome.
  Journal of gastrointestinal cancer 2021 Dillon JS, Kulke MH, Hörsch D, Anthony LB, Warner RRP, Bergsland E, Welin S, O'Dorisio TM, Kunz PL, McKee C, Lapuerta P, Banks P, Pavel M
• Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2021 Whitman J, Allen IE, Bergsland EK, Suh I, Hope TA
• Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms.
  Endocrine-related cancer 2021 Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, …
• Carcinoid Crisis-Induced Acute Systolic Heart Failure.
  JACC. Case reports 2020 Maddali MV, Chiu C, Cedarbaum ER, Yogeswaran V, Seedahmed M, Smith W, Bergsland E, Fidelman N, Kennedy JLW
• New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms.
  Abdominal radiology (New York) 2020 Saleh M, Bhosale PR, Yano M, Itani M, Elsayes AK, Halperin D, Bergsland EK, Morani AC
• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors.
  Pancreas 2020 Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, O'Dorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, …
• Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2020 Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A…
• North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19.
  Pancreas 2020 Bergsland EK, Halperin DM, Dillon JS, Dasari NA, Kunz PL, Soares HP, Pryma D, Bodei L, Hope T, Soulen MC, Mailman J, Howe JR
• Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020 Bodei L, Bergsland E, de Herder WW, Ferone D, Hicks RJ, Hope TA, Kunikowska J, Pavel M, Reidy-Lagunes D, Siveke J, Strosberg J, Dittmer U, Herrmann K
• Reply to S. Boutayeb et al.
  JCO oncology practice 2020 Lou E, Beg MS, Bergsland E, Eng C, Khorana AA, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY
• Intraarterial Peptide Receptor Radionuclide Therapy Using 90Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2020 Lawhn-Heath C, Fidelman N, Chee B, Jivan S, Armstrong E, Zhang L, Lindsay S, Bergsland EK, Hope TA
• Modifying Practices in GI Oncology in the Face of COVID-19: Recommendations From Expert Oncologists on Minimizing Patient Risk.
  JCO oncology practice 2020 Lou E, Beg S, Bergsland E, Eng C, Khorana A, Kopetz S, Lubner S, Saltz L, Shankaran V, Zafar SY
• Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study.
  Cancer 2020 Mehnert JM, Bergsland E, O'Neil BH, Santoro A, Schellens JHM, Cohen RB, Doi T, Ott PA, Pishvaian MJ, Puzanov I, Aung KL, Hsu C, Le Tourneau C, Hollebecque A, Élez E, Tamura K, Gould M, Yang P, Stein K…
• A novel stratification of mesenteric mass involvement as a predictor of challenging mesenteric lymph node dissection by minimally invasive approach for ileal neuroendocrine tumors.
  Journal of surgical oncology 2020 Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK
• Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2020 Strosberg J, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland E, Shah M, Fakih M, Takahashi S, Piha-Paul SA, O'Neil B, Thomas S, Lolkema MP, Chen M, Ibrahim N, Norwood K, Hadoux J
• A Rare Case of Carcinoid Constrictive Pericarditis.
  JACC. Case reports 2020 Wang TS, Bergsland EK, Zhang R, Ihnken K, Tolstrup K
• Residual tumor volume discriminates prognosis after surgery for neuroendocrine liver metastasis.
  Journal of surgical oncology 2019 Kasai Y, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Harun N, Kim MO, Warren RS, Bergsland EK, Nakakura EK
• Complete Response and Immune-Mediated Adverse Effects With Checkpoint Blockade: Treatment of Mismatch Repair-Deficient Colorectal Neuroendocrine Carcinoma.
  JCO precision oncology 2019 Whitman J, Kardosh A, Diaz L, Fong L, Hope T, Onodera C, Joseph N, Le D, Fisher G, Bergsland E
• Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.
  Journal of gastrointestinal cancer 2019 Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K
• Evaluation of meaningful change in bowel movement frequency for patients with carcinoid syndrome.
  Journal of patient-reported outcomes 2019 Hudgens S, Ramage J, Kulke M, Bergsland E, Anthony L, Caplin M, Öberg K, Pavel M, Gable J, Banks P, Yang QM, Lapuerta P
• Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.
  Journal of surgical oncology 2019 Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK
• Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.
  Pancreas 2019 Chan H, Moseley C, Zhang L, Bergsland EK, Pampaloni MH, Van Loon K, Hope TA
• High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.
  PloS one 2019 Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS
• Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019 Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Mahmoud N, Meyerhardt J, Morris AM, Ruíz-García E, You YN, Baxter N
• Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.
  Pancreas 2019 Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, Nakakura EK, Zhang L, Bergsland EK, Van Loon K
• Long-Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome.
  The oncologist 2019 Anthony LB, Kulke MH, Caplin ME, Bergsland E, Öberg K, Pavel M, Hörsch D, Warner RRP, O'Dorisio TM, Dillon JS, Lapuerta P, Kassler-Taub K, Jiang W
• Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.
  Translational oncology 2019 Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS
• Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.
  The oncologist 2019 Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH
• Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.
  The oncologist 2019 Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK
• Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.
  JAMA oncology 2018 Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, …
• A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.
  Molecular cancer therapeutics 2018 Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK
• Identification of high-risk human papillomavirus and Rb/E2F pathway genomic alterations in mutually exclusive subsets of colorectal neuroendocrine carcinoma.
  Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018 Shamir ER, Devine WP, Pekmezci M, Umetsu SE, Krings G, Federman S, Cho SJ, Saunders TA, Jen KY, Bergsland E, Jones K, Kim GE, Kakar S, Chiu CY, Joseph NM
• Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors.
  Journal of oncology practice 2018 Mulvey CK, Bergsland EK
• NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018.
  Journal of the National Comprehensive Cancer Network : JNCCN 2018 Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, …
• Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome.
  Clinical therapeutics 2018 Weickert MO, Kaltsas G, Hörsch D, Lapuerta P, Pavel M, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Öberg K, Welin S, Lombard-Bohas C, Ramage JK, Kittur A, Yang QM, Kulke MH
• Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl.
  Clinical therapeutics 2017 Anthony L, Ervin C, Lapuerta P, Kulke MH, Kunz P, Bergsland E, Hörsch D, Metz DC, Pasieka J, Pavlakis N, Pavel M, Caplin M, Öberg K, Ramage J, Evans E, Yang QM, Jackson S, Arnold K, Law L, DiBenedetti…
• Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.
  Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2017 Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR
• Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series.
  Familial cancer 2017 Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP
• The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.
  Pancreas 2017 Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, …
• The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.
  Pancreas 2017 Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF
• A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.
  The oncologist 2017 Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK
• Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.
  Medical oncology (Northwood, London, England) 2017 Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E
• Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.
  Journal for immunotherapy of cancer 2017 Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA
• Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.
  Pancreas 2017 Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK
• Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.
  Journal of gastrointestinal oncology 2016 Fidelman N, Kerlan RK, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP
• Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
  Pancreas 2016 Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK
• Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016 Kulke MH, Hörsch D, Caplin ME, Anthony LB, Bergsland E, Öberg K, Welin S, Warner RR, Lombard-Bohas C, Kunz PL, Grande E, Valle JW, Fleming D, Lapuerta P, Banks P, Jackson S, Zambrowicz B, Sands AT, …
• A phase II study of axitinib in advanced neuroendocrine tumors.
  Endocrine-related cancer 2016 Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK
• KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
  Annals of surgical oncology 2016 Chow OS, Kuk D, Keskin M, Smith JJ, Camacho N, Pelossof R, Chen CT, Chen Z, Avila K, Weiser MR, Berger MF, Patil S, Bergsland E, Garcia-Aguilar J
• Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.
  Hematology/oncology clinics of North America 2016 Mulvey CK, Bergsland EK
• First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Munster P, Aggarwal R, Hong D, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock…
• Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.
  EJNMMI physics 2015 Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK
• Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor.
  Abdominal imaging 2015 Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E
• A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.
  Cancer 2015 Bendell JC, Kelley RK, Shih KC, Grabowsky JA, Bergsland E, Jones S, Martin T, Infante JR, Mischel PS, Matsutani T, Xu S, Wong L, Liu Y, Wu X, Mortensen DS, Chopra R, Hege K, Munster PN
• Transcatheter pulmonic valve replacement in carcinoid heart disease.
  European heart journal. Cardiovascular Imaging 2015 Heidecker B, Moore P, Bergsland EK, Merrick SH, Rao RK
• Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy.
  Cell reports 2015 Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G
• Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015 Bergsland EK
• Is more not better?: combination therapies in colorectal cancer treatment.
  Hematology/oncology clinics of North America 2015 Bergsland EK
• Neuroendocrine tumors, version 1.2015.
  Journal of the National Comprehensive Cancer Network : JNCCN 2015 Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, …
• The spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlap.
  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting 2015 Klimstra DS, Beltran H, Lilenbaum R, Bergsland E
• Bone metastases and skeletal-related events from neuroendocrine tumors.
  Endocrine connections 2014 Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK
• Neuroendocrine tumors of unknown primary: is the primary site really not known?
  JAMA surgery 2014 Bergsland EK, Nakakura EK
• Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide.
  Endocrine-related cancer 2014 Kulke MH, O'Dorisio T, Phan A, Bergsland E, Law L, Banks P, Freiman J, Frazier K, Jackson J, Yao JC, Kvols L, Lapuerta P, Zambrowicz B, Fleming D, Sands A
• B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.
  Cancer cell 2014 Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM
• 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.
  Journal of gastrointestinal cancer 2014 Fidelman N, Kerlan RK, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP
• Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.
  Cancer chemotherapy and pharmacology 2014 Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J, Maughan T, Castillo MG, Iveson T, Yin D, Green S, Bergsland EK
• A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
  British journal of cancer 2013 Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK
• Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.
  Oncogene 2013 Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS
• Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
  Annals of oncology : official journal of the European Society for Medical Oncology 2013 Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB, Venook AP
• Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors.
  Seminars in oncology 2013 Bergsland EK
• The evolving landscape of neuroendocrine tumors.
  Seminars in oncology 2013 Bergsland EK
• Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.
  American journal of clinical oncology 2012 Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA
• Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.
  Pancreas 2012 Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK
• Neuroendocrine tumors.
  Journal of the National Comprehensive Cancer Network : JNCCN 2012 Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, …
• Systemic therapy for advanced carcinoid tumors: where do we go from here?
  Journal of the National Comprehensive Cancer Network : JNCCN 2012 Paulson AS, Bergsland EK
• Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.
  Investigational new drugs 2012 Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM
• Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.
  Annals of surgery 2011 Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM, Timing of Rectal Cancer Response to Chemoradiation Consortium
• Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC
• Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.
  The Journal of surgical research 2010 Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK
• Identification of unknown primary tumors in patients with neuroendocrine liver metastases.
  Archives of surgery (Chicago, Ill. : 1960) 2010 Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK
• The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.
  Endocrine-related cancer 2010 Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK
• A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.
  Cancer chemotherapy and pharmacology 2010 Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA
• Glycemic control in patients with insulinoma treated with everolimus.
  The New England journal of medicine 2009 Kulke MH, Bergsland EK, Yao JC
• Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.
  Endocrine-related cancer 2008 Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK
• Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.
  Pancreas 2008 Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA
• Activity of sunitinib in patients with advanced neuroendocrine tumors.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008 Kulke MH, Lenz HJ, Meropol NJ, Posey J, Ryan DP, Picus J, Bergsland E, Stuart K, Tye L, Huang X, Li JZ, Baum CM, Fuchs CS
• A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?
  Investigational new drugs 2008 Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA
• Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.
  Cancer investigation 2008 Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA
• Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma.
  Clinical colorectal cancer 2008 Berlin JD, Venook A, Bergsland E, Rothenberg M, Lockhart AC, Rosen L
• Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ
• Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
  Journal of the National Cancer Institute 2007 Scappaticci FA, Skillings JR, Holden SN, Gerber HP, Miller K, Kabbinavar F, Bergsland E, Ngai J, Holmgren E, Wang J, Hurwitz H
• Systemic and regional nonsurgical therapy--what is the optimal strategy for metastatic neuroendocrine cancer?
  Surgical oncology clinics of North America 2007 Nakakura EK, Venook AP, Bergsland EK
• Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region.
  Hematology/oncology clinics of North America 2007 Nakakura EK, Bergsland EK
• A phase II study of fixed-dose rate gemcitabine plus low-dose cisplatin followed by consolidative chemoradiation for locally advanced pancreatic cancer.
  International journal of radiation oncology, biology, physics 2007 Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA
• Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006 Kulke MH, Bergsland EK, Ryan DP, Enzinger PC, Lynch TJ, Zhu AX, Meyerhardt JA, Heymach JV, Fogler WE, Sidor C, Michelini A, Kinsella K, Venook AP, Fuchs CS
• Pancreatoblastoma in an adult: case report and review of the literature.
  Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2006 Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK
• Targeting growth factors and angiogenesis; using small molecules in malignancy.
  Cancer metastasis reviews 2006 Wanebo HJ, Argiris A, Bergsland E, Agarwala S, Rugo H
• When does the presence of the target predict response to the targeted agent?
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Bergsland EK
• Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA
• Anti-angiogenic strategies in gastrointestinal malignancies.
  Current treatment options in oncology 2005 Whisenant J, Bergsland E
• Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer.
  British journal of cancer 2005 Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA
• Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S
• Fractional genomic alteration detected by array-based comparative genomic hybridization independently predicts survival after hepatic resection for metastatic colorectal cancer.
  Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Mehta KR, Nakao K, Zuraek MB, Ruan DT, Bergsland EK, Venook AP, Moore DH, Tokuyasu TA, Jain AN, Warren RS, Terdiman JP, Waldman FM
• Update on clinical trials targeting vascular endothelial growth factor in cancer.
  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2004 Bergsland EK
• Vascular endothelial growth factor as a therapeutic target in cancer.
  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2004 Bergsland EK
• Angiogenesis in colorectal cancer: therapeutic implications and future directions.
  Hematology/oncology clinics of North America 2004 Allen J, Bergsland EK
• Maximizing the potential of bevacizumab in cancer treatment.
  The oncologist 2004 Bergsland E, Dickler MN
• Couples therapy at end of life.
  Psycho-oncology 2003 Mohr DC, Moran PJ, Kohn C, Hart S, Armstrong K, Dias R, Bergsland E, Folkman S
• Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors.
  The Journal of clinical investigation 2003 Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D
• Immune enhancement of skin carcinogenesis by CD4+ T cells.
  The Journal of experimental medicine 2003 Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D
• Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003 Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E
• Tumor-associated hypoglycemia from metastatic colorectal adenocarcinoma: case report and review of the literature.
  Digestive diseases and sciences 2003 Ko AH, Bergsland EK, Lee GA
• Shedding old paradigms: developing viruses to treat cancer.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002 Bergsland EK, Venook AP
• Molecular mechanisms underlying the development of hepatocellular carcinoma.
  Seminars in oncology 2001 Bergsland EK
• Hepatocellular carcinoma.
  Current opinion in oncology 2000 Bergsland EK, Venook AP
• Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.
  The Journal of clinical investigation 2000 Hanahan D, Bergers G, Bergsland E
• Human acellular dermal matrix as a novel model of malignant epithelial cell invasion.
  Invasion & metastasis 1997 Bullard KM, Banda MJ, Arbeit JM, Bergsland E, Young DM